Efficacy and safety of deferoxamine in moderately ill COVID-19 patients: An open label, randomized controlled trial
Deferoxamine had no significant impact on improving moderately ill patients with COVID-19. However, it was well-tolerated in the patients, and this intervention demonstrated a safe profile of adverse events.
Authors
- Parivash Davoodian (ORCID: https://orcid.org/0000-0002-3303-7649)
- Omid Safa (ORCID: https://orcid.org/0000-0003-2119-8936)
- Ali Ameri (ORCID: https://orcid.org/0000-0003-0168-4320)
- Mohammad Fathalipour (ORCID: https://orcid.org/0000-0002-4568-7024)
- Farnaz Pourseyedi
- Soheil Hassanipour
Institutions
- Guilan University of Medical Sciences (IR)
- Hormozgan University of Medical Sciences (IR)
Publication Details
- Journal
- Medicine
- Published
- 2024-08-23
- DOI
- https://doi.org/10.1097/md.0000000000039142
- Citations
- 1
- Primary Topic
- Hemoglobinopathies and Related Disorders
- Type
- article
- Field-Weighted Citation Impact
- 0.44
Funders
- Hormozgan University of Medical Sciences